ClinicalTrials.gov lists 11 registered trials of Tesofensine: 0 recruiting or about to, 0 running, 11 completed, 4 with results posted. The largest is An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type (430 people).
11registered trials
0recruiting now
0running
11completed
0in phase 3
4with results posted
Registered trials by phase. Phase 3 trials are the large ones that decide approval.
Each bar runs from a trial's start to its planned end; faded bars have no end date. Click a bar to open the trial.
Studying: Healthy Male Subjects · NCT03286829
A randomized, open-label, single-dose, parallel-arm, Phase 1 study to investigate the pharmacokinetic profile of a fixed-dose combination tablet of tesofensine and metoprolol (Tesomet) and co-administration of tesofensine plus commercial metoprolol in adult healthy subjects
Studying: Type 2 Diabetes Mellitus · NCT02737891
Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus
Studying: Hypothalamic Injury-induced Obesity (HIO) · NCT03845075
Double-blind, randomized, placebo-controlled, single- center study followed by an open-label extension period. • The study will have two parts: * Part 1: 24 weeks double-blind treatment (DB), followed by * Part 2: 24 weeks open-label extension (OLE) - all subjects still participating at the end of Part 1 will be given an option to continue for additional 24 weeks on the active drug if evaluated eligible by the Investigator
Studying: Confirmed Genetic Diagnosis of Prader-Willi Syndrome · NCT03149445
Two-centre, double-blind, placebo-controlled, randomized, and multiple-dose clinical study followed by two open label extension periods.
Studying: Alzheimer Disease · NCT00153010
Objectives: The objective of this study will be to determine the safety, tolerability, drug blood levels, and efficacy of each of three doses of NS 2330 (Tesofensine) given once daily compared with placebo in patients with mild to moderate Dementia of the Alzheimer's Type.
Studying: Parkinson Disease · NCT00148486
To demonstrate efficacy and dose-response of NS 2330 versus placebo in patients with early Parkinson's Disease in 14 weeks of treatment, and to investigate the safety and tolerability of NS 2330 in these patients.
Studying: Parkinson Disease · NCT00148512
The primary objective of this exploratory study is to investigate the efficacy and safety of tesofensine in daily doses (from 0.125 mg to 1.0 mg) in comparison to placebo, over a 14-week treatment period in levodopa treated Parkinson patients with motor fluctuations.
Studying: Obesity · NCT00394667
Purpose: To evaluate the efficacy on weight reduction, metabolic parameters and safety of tesofensine versus placebo in obese patients
Studying: Obesity · NCT00481104
Purpose of the study is to evaluate the long term safety of tesofensine in obese patients
Studying: Parkinson's Disease · NCT00006077
This study will evaluate the effects of an experimental drug called NS2330 on Parkinson's disease symptoms and on dyskinesias (involuntary movements) that develop as a result of long-term treatment with levodopa. This drug prevents the neurotransmitter dopamine from entering nerve cells. Patients between 18 and 75 years old who have moderately advanced Parkinson's disease and motor problems resulting from levodopa therapy may be eligible for this 5-week study. Candidates will have a complete medical history and physical examination with a detailed neurological evaluation. If needed, some pati…
Studying: Obesity · NCT00428415
Purpose: To evaluate the effect of tesofensine on energy balance
Registered trials include ones that haven't published results yet. Trials are matched on the compound's name and code names (Tesofensine, NS2330) in the listed interventions.